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1. Introduction 
Behavioural and psychological symptoms are common in dementia. These symptoms include 
depression and anxiety, psychotic symptoms, wandering, agitated behaviour and sleep 
disorders, and are collectively known as the behavioural and psychological symptoms of 
dementia (BPSD). These symptoms confer a large proportion of the social burden of dementia 
[1,2], and are important targets for intervention in dementia patients [3]. Yet these symptoms 
are not restricted to those with dementia. Many behavioural and psychological problems are 
also present in a significant proportion of the non-demented older population [4,5]. 
Behavioural and psychological symptoms have been associated with cognitive impairments 
not sufficient for a diagnosis of dementia, although their prevalence and relationship to 
cognitive impairments are not clear. Two recent reviews have highlighted the variation in 
estimates of the prevalence of behavioural and psychological symptoms in those with mild 
cognitive impairment (MCI) and suggested that differences in the settings of studies, the 
characteristics of participant groups, and the definitions of symptoms and of MCI contribute to 
this variation [6,7]. In this work we use data from the population representative Cognitive 
Impairment Through Aging Study (CogItA) to explore the relationship between behavioural 
and psychological symptoms with the different classifications of MCI and in different 
neuroimaging pattern . 
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2. Mild cognitive impairment 
 
Improvements in health care over the past 50 years have extended average life 
expectancy, which has resulted in a substantial increase in the numbers of individuals over 65 
years of age.(8) Many elderly people complain of impaired memory (9) and do less well than 
the young in various cognitive tasks, particularly those that assess memory; (10) these findings 
suggest that memory impairments are a common consequence of the ageing process.  
Careful cross-sectional examination of cognitive function among elderly people, 
however, reveals a range of cognitive impairment including deficits in various domains in the 
absence of clinically defined dementia. (11,12)  
Gradual decline in cognitive ability is characteristic in longitudinal studies of elderly 
people. Although this is consistent with the hypothesis that normal ageing is accompanied by 
mental decline, differences between individual trajectories of change suggest that much of the 
age-related cognitive decline reflects the inclusion of individuals with incipient dementia.(13)  
The notion that incipient dementia is common among elderly individuals is further 
supported by neuropathological studies that reveal evidence of Alzheimer’s disease (AD) 
years before clinical symptoms present.(14,15) Extensive AD pathology can rarely be found in 
individuals with no detectable symptoms.(14,16) AD pathology is, however, more likely to 
occur in patients that show memory impairment, even if they’re not demented yet.(15)  
Clinical studies of elderly individuals with memory impairment also reveal a rapid rate 
of conversion to AD, reaching as high as 15% per year. This evidence suggests that significant 
memory impairment, short of dementia and often denoted as mild cognitive impairment 
(MCI), in elderly people may be a transition phase between the normal ageing process and 
AD.(17,18)  
Although many individuals with MCI complain of memory loss, impairments in other 
cognitive domains also occur,(19) and not all MCI patients go on to develop AD,(10) 
particularly when MCI is studied in the general population.(20)  
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The assumption that MCI may represent a transition state between normal cognitive 
decline due to ageing and dementia offers possibilities for early diagnosis and potential 
treatment with the aim of delaying the onset or preventing dementia.(14) 
 
 
2.1 Background and conceptual development 
 
Many attempts have been made to define the clinical entity of declined cognitive 
abilities associated with ageing. In the early part of the 19th century, Prichard (22) identified 
the earliest stage of dementia as impairment of recent memory with intact remote memory.  
More than a century later, Kral (23) espoused a contrasting point of view, with his 
description of benign senescent forgetfulness, in which fairly unimportant data and parts of an 
experience are not recalled and in which the forgotten data seem to belong to the remote past 
rather than the recent past. Recognition that dementia can have a long prodromal phase has led 
to active investigation of individuals with cognitive impairment without dementia. Work in 
this area has created many definitions (table 1).(26,31, 39. 44) 
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Tab.1 Definition of MCI 
 
 
 
 
In 1982, two clinical staging systems were published, which continue to be used today 
by clinicians to assess the boundaries of ageing and dementia. These are the clinical dementia 
rating (CDR) (24) and the global deterioration scale for ageing and dementia (GDS). (25) The 
CDR distinguishes a stage of questionable dementia (CDR 0·5) from people defined healthy 
(CDR 0) and those with mild dementia (CDR 1). Individuals at CDR 0,5 have mild consistent 
forgetfulness and doubtful or mild impairment in independent function at the usual level in 
job, shopping, business and financial affairs, and volunteer and social groups. 
Definitions of dementia were published in 1980 by the American Psychiatric 
Association (26) and in 1984 by the National Institute of Neurological and Communicative 
Disorders and Stroke/the Alzheimer’s Disease and Related Disorders Association 
(NINCDS/ADRDA), (27) which remain today as benchmarks for clinicians.  
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The American Psychiatric Association’s primary degenerative dementia definition 
notes that the diagnosis should be restricted “to cases in which there is clear evidence of 
progressive and significant deterioration of intellectual and social or occupational 
functioning”. (26)  
The definition by McKhann and colleagues (27) also notes that a diagnosis of probable 
Alzheimer’s disease should include deficits in two or more areas of cognition, with 
progressive worsening of memory and other cognitive functions.  
Diagnosis is lent support by impaired activities of daily life. Hence, from these 
definitions, the CDR 0·5 stage of questionable dementia includes mild dementia and mild 
cognitive impairment, but allows for such affected individuals to have measurable deficits in 
several areas of cognition without meeting criteria for dementia. 
The term mild cognitive impairment was first used in association with stage 3 of the 
GDS. (25, 28) This scale identifies seven clinical stages, of which four range from normality 
to mild dementia. Stage 1 individuals are free of both subjective and objective clinical deficits. 
Those at stage 2 have subjective deficits only, such as self-perceived difficulties remembering 
names. Perhaps the best current terminology for this disorder is subjective cognitive 
impairment.  
People at GDS stage 3 have subtle deficits in cognition and may have some impairment 
in executive functioning that affects complex occupational and social activities. GDS stage 4 
individuals have clear deficits in cognition and functioning with reduced performance in 
instrumental activities of daily life, such as preparing meals and managing personal financial 
affairs. People at GDS stage 4 fulfil criteria for mild dementia.  
According to Reisberg, (25) the GDS 3 description of mild cognitive impairment 
accords with that subsequently formulated by an international working group (29) and 
describes a severity range of cognitive and functional impairment largely in keeping with 
other subsequent definitions described below. 
Petersen (30) says it is important to note that the GDS and the CDR are severity rating 
scales and not diagnostic instruments. Some investigators have equated GDS 3 or CDR 0,5 to 
mild cognitive impairment, but Petersen believes that this practice might not always be 
correct, stating that: “as severity scales, these stages may correspond to mild cognitive 
impairment or may describe individuals with very mild dementia.” As such, Petersen believes 
that the rating scales are not synonymous with the syndrome of mild cognitive impairment. 
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Reisberg and associates disagree with respect to the GDS 3 stage, which they believe to be 
fully consistent with, for example, the definition of mild cognitive impairment posed in the 
opening statement of this report.  
As noted above, the CDR 0,5 stage of questionable dementia is a broad category that 
encompasses mild dementia and mild cognitive impairment. Reisberg points out that the 
global staging definition of mild cognitive impairment has advantages of inclusivity, whereas 
other definitions of the disorder are frequently more restrictive—eg, from an epidemiological 
standpoint.  
For example, the amnestic subtype of mild cognitive impairment described below and 
in the panel requires memory complaints. (30) Many individuals with mild cognitive 
impairment deny they have the disorder and do not report symptoms, although they 
nevertheless show signs of cognitive impairment consistent with the disorder that are evident 
to clinicians or informants.  
The GDS 3 definition of mild cognitive impairment—unlike the preceding GDS 2 
stage of subjective cognitive impairment and the amnestic subtype of mild cognitive 
impairment—does not require memory complaints; only signs of the disorder are required for 
GDS stage 3 assignment. Hence the GDS stage 3 definition of mild cognitive impairment is 
more encompassing of individuals with these clinical signs than, for example, the amnestic 
category. 
The model of cognitive impairment no dementia (CIND) includes all individuals 
falling in between healthy and demented states, and has been used in population-based 
epidemiological studies such as the Canadian Study of Health and Aging(31) and the 
Indianapolis Study of Health and Aging.(32) As originally derived by the investigators of the 
Canadian study, this model encompasses many disorders, from circumscribed memory 
impairment to chronic alcohol and drug use, psychiatric illness, mental retardation, and 
vascular pathologies.  
CIND represents cognitive impairment that may or may not progress to dementia. 
Another perspective on this model, described by Petersen (33) and Winblad and colleagues, 
(29) is that although previous criteria for mild cognitive impairment were specific to isolated 
deficits in memory, developments have extended them so that the definition of mild cognitive 
impairment now includes a broad range of cognitive deficits and clinical subtypes with many 
potential causes.  
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In other words, mild cognitive impairment and CIND could previously be 
distinguished by the fact that mild cognitive impairment referred to isolated memory 
deficits—now called amnestic mild cognitive impairment—whereas CIND included global 
cognitive impairment and deficits in several cognitive domains.  
Currently, attempts are being made (33) to broaden the definition of mild cognitive 
impairment to include non-memory deficits and impairment in several cognitive domains, with 
causal mechanisms including degenerative, vascular, and psychiatric factors.  
Findings of longitudinal population studies, which have been undertaken using various 
definitions of mild cognitive impairment adapted to epidemiological research, have shown a 
prevalence in the general elderly population between 3% and 19%, with an incidence of 8–58 
per 1000 per year, and a risk of developing dementia of 11–33% over 2 years.(34)  
Conversely, findings of population-based studies have shown that up to 44% of 
patients with mild cognitive impairment at their first visit were estimated to return to normal a 
year later.(34, 35) 
These epidemiological studies underline the fact that there are many factors affecting 
cognition performance in elderly populations apart from neurodegenerative disorders, 
including education, vascular risk factors, psychiatric status, genetic background, hormonal 
changes, and use of anticholinergic drugs, and that these factors can account for why many 
cases of mild cognitive impairment are reversible.  
Patients referred to memory clinics and other specialised centres are unlike the general 
population in that they are seeking services for a perceived memory disorder. At these centres, 
they are diagnosed after detailed, systematic, clinical and neuropsychological assessments. In 
these clinical research settings, individuals with mild cognitive impairment have been shown 
to progress to dementia (generally Alzheimer’s disease) at a rate of 18% per year. (36)  
Similarly, those diagnosed with amnestic mild cognitive impairment with the research 
criteria defined by Petersen and colleagues (tab.2), (30) who also fulfil exclusion criteria for 
various medical, psychiatric, and neurological disorders, have a high rate of progression to 
dementia, particularly Alzheimer’s disease.  
In a 3-year multicentre randomised clinical trial, a 16% per year rate of progression to 
Alzheimer’s disease was noted with the definition of amnestic mild cognitive impairment. (37)  
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Amnestic subtype of mild cognitive impairment 
Memory complaint, preferably corroborated by an informant 
Memory impairment relative to age-matched and education-matched healthy people 
Typical general cognitive function 
Largely intact activities of daily living 
Not clinically demented  
Tab.2 Peterson’s MCI Criteria   
This rate accords with findings of previous studies in which similar inclusion and 
exclusion criteria were used.(38) Findings of another study, in which the same definition of 
amnestic mild cognitive impairment was used for patients referred on the basis of history of 
progressive memory changes, showed a progression rate to Alzheimer’s disease of 41% after 1 
year and 64% after 2 years.(39) Thus, application of the same amnestic criteria can lead to 
different progression rates despite baseline similarity in cognitive performance.  
This finding suggests a need to broaden clinical criteria for amnestic mild cognitive 
impairment (and probably mild cognitive impairment at large) to include history and duration 
of symptom progression and more explicit acknowledgment of the exclusion criteria applied in 
various studies.  
The category of mild neurocognitive disorder in the diagnostic and statistical manual, 
4th edition, is similar, but not identical, to the syndrome of mild cognitive impairment. 
Research criteria for mild neurocognitive disorder include the presence of two or more 
disturbances, including impairment in memory, executive function, attention or speed of 
processing, perceptual-motor abilities, and language.  
Two cognitive domains must show decline and cause impairment in social, 
occupational, or another area of function. Objective evidence has to be present of a 
neurological or general medical disorder that is judged to be caused by the cognitive 
disturbance.  
In summary, patients defined by the terms CDR 0,5, GDS stage 3, CIND, and mild 
cognitive impairment represent a large segment of the population older than age 65 years. The 
prognosis in terms of progression to dementia is more heterogeneous in population studies 
than in the setting of specialised clinics and is driven by the nosological and exclusionary 
criteria being used in either setting.  
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2.2 Pathophysiology 
 
Much clinical evidence exists for the detrimental effects of anticholinergic drugs on 
cognition.(40) A central cholinergic deficit is thought to be present in amnestic mild cognitive 
impairment, related to loss of neurons in the nucleus basalis of Meynert, (41) although 
findings of a post-mortem study showed upregulation of choline acetyl transferase activity in 
the frontal cortex and hippocampus.(42)  
This upregulation could be a compensatory mechanism, which is suggested by 
recruitment of memory and attentional networks, shown by functional magnetic resonance 
imaging.(43) The role of cerebrovascular disease in mild cognitive impairment is probably 
under-represented, particularly in population studies in which brain imaging has not been 
undertaken.(44)  
Findings of the Religious Order Study (45) indicated that cerebrovascular involvement 
in mild cognitive impairment is intermediate between that seen  in ageing and early 
Alzheimer’s disease. Both cerebrovascular disease and neurodegenerative features were 
shown to contribute to mild cognitive impairment.  
The importance of white-matter lesions and small lacunar infarcts is becoming 
increasingly apparent in vascular cognitive impairment.(46) In view of the fact that 
cerebrovascular disease is frequent in elderly individuals, and that treatment of 
cerebrovascular risk factors constitutes one of the most important prevention strategies for 
Alzheimer’s disease and vascular dementia, more research is needed on vascular mild 
cognitive impairment or vascular CIND.  
These disorders need to be defined operationally, as was done for mild cognitive 
impairment associated with subcortical cerebrovascular disease.(47) The role of amyloid 
deposition and neurofibrillary tangle formation in mild cognitive impairment has not been 
studied extensively yet. 
Pathological findings of neurofibrillary tangles in the mesial temporal structures do 
correlate with mild cognitive impairment. (48, 49) Compared with people with dementia and 
those without cognitive impairment, individuals with mild cognitive impairment have 
intermediate amounts of Alzheimer’s disease pathological findings identified by silver stain, 
(48) with amyloid deposition and tau-positive tangles (50) in the mesial temporal lobes.  
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Mutations in apolipoprotein E alleles clearly raise the risk of progression from 
amnestic mild cognitive impairment to Alzheimer’s disease. (37, 51, 52) This mutation alters 
cholesterol transport and synaptic plasticity.(53)  
Other gene mutations are likely to be identified, which will be of relevance to the 
progression of mild cognitive impairment towards dementia.  
In summary, a combination of causal factors are interacting in patients with mild 
cognitive impairment, including cholinergic dysfunction, white-matter lesions and cerebral 
infarctions, extracellular amyloid deposition, and intracellular neurofibrillary tangle formation. 
Apolipoprotein E4 allele status can increase the risk of progression from mild cognitive 
impairment to Alzheimer’s disease. 
 
2.3 Diagnosis 
 
In terms of research diagnostic criteria, there is uncertainty about whether a lumping-
together approach to mild cognitive impairment (54) is preferable to a splitting approach, with 
various categories of the disorder. (55) 
Prospective cohort studies are underway to establish whether amnestic and non-
amnestic subtypes of mild cognitive impairment (figure) (56) have different prognoses for 
progression to dementia and which type of dementia they predict (56) and their effect on 
survival times. (57)  
It is possible that all progressive dementias have their own predementia states.(58) The 
operational definition of amnestic mild cognitive impairment proposed by Petersen (tab. 2)(9) 
has been used repeatedly in randomised controlled trials, with some variations on the test for 
delayed recall and cut-off scores to distinguish people with mild cognitive impairment from 
healthy individuals. (37, 38,59, 60) 
These apparently minor differences in entry criteria for the level of memory 
impairment are associated with different rates of progression to Alzheimer’s disease, ranging 
from 5% to 16% per year. Other factors affect the rate of progression, such as the number of 
people carrying the apolipoprotein E4 allele.  
It should be noted that these trials applied inclusion and exclusion criteria similar to 
those proposed by McKhann and colleagues (27) for Alzheimer’s disease, with the important 
exception of the presence of dementia and the size of the cognitive and functional decline. 
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An international working group on mild cognitive impairment formulated specific 
recommendations for criteria, including: (22) the individual is neither normal nor demented; 
(23) there is evidence of cognitive deterioration, shown by either objectively measured decline 
over time or subjective report of decline by self or informant in conjunction with objective 
cognitive deficits; and (24) activities of daily life are preserved and complex instrumental 
functions are either intact or minimally impaired. (9) 
These criteria serve to expand the construct of mild cognitive impairment to involve 
cognitive domains other than memory and make it a prodrome to multiple types of dementia.  
Standard neuropsychological tests have established that poor performance on delayed 
recall and executive function tests indicate a high risk of progression to dementia,(28, 61, 62) 
particularly delayed recall, since this measure was a highly accurate predictor of progression 
to Alzheimer’s disease in longitudinal studies of 2–10 years’ duration in clinical samples (63, 
64) and large epidemiological samples.(65) 
There is a need for sensitive but user-friendly cognitive tests for clinicians, such as the 
Montreal cognitive assessment. (66) This test is a useful complement to the mini-mental state 
examination,(67) which is within the normal range in most patients with mild cognitive 
impairment.  
Informant rating scales significantly improve the accuracy of the mini-mental state 
examination in predicting progression to Alzheimer’s disease.(68)  
Although cognitive symptoms and tests have been the core features of mild cognitive 
impairment up to now, there is increasing awareness of a behavioural component, which 
includes anxiety, depression, irritability, and apathy. (69, 70)  
The presence of behavioural and psychological signs, including depression, predicts a 
high likelihood of progression to dementia. (71) A semi-structured interview to psychiatric 
symptoms and use of standardised scales such as the neuropsychiatric inventory (72) have 
shown an important contribution of behavioural changes to mild cognitive impairment in a 
clinical trial setting.(60) 
Depressive symptoms can contribute to mild cognitive impairment and have been 
shown to modify positive predictive value, specificity, and sensitivity in randomised 
controlled trials.(73) It is likely that future formulations of the broader definition of mild 
cognitive impairment will include non-cognitive symptoms that might be important in the 
prodrome of disorders such as frontotemporal dementia and Lewy body dementia.  
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Difficulties remain in defining the boundaries between normal ageing and mild 
cognitive impairment, and between mild cognitive impairment and mild dementia.(74) Many 
of these distinctions depend on the degree of functional impairment.  
Findings of epidemiological studies have shown that subtle difficulties in the 
performance of everyday activities (eg, complex hobbies, finance handling) are common in 
individuals with mild cognitive impairment 2 years before a diagnosis of dementia, (63) 
whereas overt difficulties in certain abilities (use of the telephone, finances, transportation, 
drugs) signal the onset of dementia. (75)  
The lack of awareness of such impairments in people with mild cognitive impairment 
has been postulated to be predictive of progression to dementia. (76)  
Individuals with memory complaints and informants should be asked about 
performance on hobbies, executive level tasks, and instrumental activities of daily life. (77, 
78)  
Mild cognitive impairment is also accompanied by other changes, such as balance and 
coordination. (79) A structured assessment of functional capacities will become increasingly 
important in determining the point at which people with mild cognitive impairment progress to 
dementia. Analysis of data from randomised controlled trials such as the Memory Impairment 
Study (80) could help in this respect.  
Neuroimaging and electrophysiological tests for the workup of mild cognitive 
impairment could be the same as those used in early dementia. Several methods are sensitive 
for mild cognitive impairment, including brain imaging with MRI, (81, 82) positron emission 
tomography, (83, 84) and quantitative electroen cephalography. (85, 86)  
Medial temporal lobe atrophy on magnetic resonance imaging and hypometabolism on 
fluorodeoxyglucose-positron emission tomography have been recorded in people with mild 
cognitive impairment compared with cognitively normal individuals, (82, 88) and presence of 
these signs has a high predictive value for progression to dementia. (89, 90)  
Biomarkers in cerebrospinal fluid under study include total tau, phosphotau epitopes, 
and the 42 aminoacid form of β amyloid. (91, 92) Specific phosphotau epitopes have met 
criteria for an ideal biological marker candidate, with properties for both classification and 
early diagnosis.(82, 93)  
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Evidence suggests that phosphotau 231 and isoprostane can increase the diagnostic 
accuracy of conventional cognitive and magnetic resonance assessments in people with mild 
cognitive impairment.(92) 
Many of these biomarkers have been selected by the National Institute on Aging 
biological markers working group (95) as feasible core biomarkers suitable for multicentre 
longitudinal studies of Alzheimer’s disease with special consideration given to mild cognitive 
impairment.  
A large study from the Alzheimer’s Disease Neuroimaging Initiative has just begun 
investigating the role of imaging measures and biomarkers in predicting progression to 
dementia in individuals with mild cognitive impairment.  
In summary, research diagnostic criteria are being validated for the different subtypes 
of mild cognitive impairment, with emphasis on amnestic mild cognitive impairment. Until 
such validation is available from prospective cohort studies, a pragmatic approach to mild 
cognitive impairment has been proposed by Gauthier and Touchon (96) to distinguish 
subtypes in clinical practice, based on the most prominent feature at a given time, from 
amnestic to dysphoric, vascular, or associated with other medical disorders.  
It might be time to consider revisions of the international classification of mental and 
behavioural disorders and of the diagnostic and statistical manual of mental disorders, to 
include specific diagnostic criteria for mild cognitive impairment or its different subtypes.  
Furthermore, an update to the NINCDS/ ADRDA criteria for Alzheimer’s disease (27) 
should be considered, to include a prodromal or very early stage of Alzheimer’s disease that 
would correspond to amnestic mild cognitive impairment, as defined in the clinical trials 
described in the next section. 
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Tab.3 Outline the syndrome of mild cognitive impairment. 
Figure swos MCI with predominant amnestic versus non-amnestic neuropsychological feautures, potential 
prodrome to neurodegenerative disorder such as Alzheimer’s desease, frontotemporal dementia, Lewy Body 
disease, or caused by vascular cognitive impairment, psychiatric disordersuch as depression or as a prodrome to 
other medical disorder, including metabolic and nutritional deficiencies, upper airway obstruction, andhead 
trauma.(56) 
 
2.4 Management 
 
The first wave of clinical trials aimed at symptomatic drug treatment for amnestic mild 
cognitive impairment over 6 months to 3 years have been largely unsuccessful.(97) Results 
from the Memory Impairment Study (37) showed no significant differences in the probability 
of progression from amnestic mild cognitive impairment to Alzheimer’s disease in patients 
allocated vitamin E or donepezil, compared with placebo, during the 3 years of treatment, 
although significant differences were recorded favouring the donepezil group on various 
measures during the first 12 months of the study including delay of diagnosis of Alzheimer’s 
disease.(37)  
Furthermore, there was a prolonged response to donepezil over 24 months in the 
apolipoprotein E4 carrier subgroup. Potential reasons for the apparent lack of sustained benefit 
of the cholinesterase inhibitors might be the compensatory upregulation of central cholinergic 
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activity, lack o sensitivity of the cognitive outcomes (ceiling effects), and heterogeneity of 
patients. If there is benefit from these inhibitors, it seems to be limited and transient. (98) 
Conversely, randomised controlled trials of cholinesterase inhibitors and other 
pharmacological drugs are worth pursuing in mild cognitive impairment, possibly targeting 
populations at high risk of progression to dementia, since there are indications that 
postponement between mild cognitive impairment and manifest dementia could result in short-
term economic benefis of US$5300 per patient per year (99) and advantages for individuals 
with mild cognitive impairment and their families.  
It should be noted that resource use and costs attributable to the disorder during the 
mild cognitive impairment phase are low, and possibilities to detect intervention effects on 
direct costs are also low during this phase.  
However, many people with mild cognitive impairment retire from their occupations 
and other productive activities as the disorder progresses, and economic models should take 
into consideration productivity losses.  
Additionally, from clinical experience, it is known that depressive symptoms are 
common in people with mild cognitive impairment.  
However, the extent to which these symptoms cause resource use in terms of informal 
care is not known. Encouraging results have been reported from uncontrolled studies using 
cognitive training.(100, 101)  
Large effect sizes have been noted within the range for healthy elderly people (102) 
and better than that for patients with Alzheimer’s disease.(103)  
The success of cognitive training seems to be dependent on the level of severity across 
the range of normal ageing to dementia.  
These findings in individuals with mild cognitive impairment need to be confirmed in 
randomised controlled trials.  
The management of patients with mild cognitive impairment is currently non-specific: 
control of vascular risk factors; treatment of concomitant disorders such as depression and 
hypothyroidism; and phasing out anticholinergic drugs.  
Many people with mild cognitive impairment are very aware of their difficulties and 
seek information about the nature of their disorder and their outlook. They are also interested 
in coping strategies, particularly if they are in demanding occupational settings.  
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Since these patients are at higher risk of dementia and death than usual, they need 
sensitive counselling about such risks and the current lack of certainty in predicting prognosis. 
It would not be appropriate to falsely reassure them that they are healthy, since they 
should have the opportunity to make future plans while fully competent to do so, including 
advance directives for power of attorney in case of incapacity.  
A caregiver burden has already been identified for spouses of people with mild 
cognitive impairment, for which selective preventive interventions to keep psychological 
wellbeing to a maximum should be considered.(104)  
Currently, there is debate about whether the term mild cognitive impairment should be 
used at all in clinical practice, in view of the heterogeneity of progression to dementia and the 
possibility of reverting back to normal.  
Caution should thus be exercised in using this term. Some researchers are attempting to 
broaden the discussion about mild cognitive impairment to the political, philosophical, and 
economic implications of anti-ageing drugs.(105)  
Systematic screening for mild cognitive impairment in asymptomatic elderly people is 
not recommended because of insufficient data about its usefulness. On the other hand, 
spontaneous memory complaints from people older than 50 years, particularly if corroborated 
by an informant, should lead to a medical assessment as per standard clinical practice for 
individuals suspected of early dementia.  
Mild cognitive impairment is regarded as a medical diagnosis by some clinicians, as 
suggested in the American Academy of Neurology practice parameter statement that “patients 
with a mild cognitive impairment should be recognized and monitored for a cognitive and 
functional decline due to their increased risk for subsequent dementia”, (106) a state of risk 
considered by other authors, possibly amenable to prevention.  
However, in view of the variation in specificity with respect to the outcome of 
amnestic mild cognitive impairment, one must be cautious in presenting a diagnosis such as 
incipient Alzheimer’s disease prematurely. 
 
 
2.5 Prevention 
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Although no specific disease-modifying treatment has yet been shown to be effective 
for any of the degenerative dementias, control of risk factors might prove useful. The best 
evidence available so far is in the control of isolated systolic hypertension. (44)  
The idea of interventional epidemiology proposed by Ritchie (34) for mild cognitive 
impairment will probably lead to international randomised controlled trials linking the 
consortia of investigators interested in the causes and treatment of mild cognitive impairment 
and dementia (European Alzheimer’s disease consortium, Alzheimer’s disease cooperative 
study in the USA, and consortium of Canadian centres for clinical cognitive research). 
 
2.6 Clinical continuum of cognitive decline 
 
The advent of current understanding of mild cognitive impairment and the clear 
findings that the disorder is a frequent precursor of overt dementia raises the question of the 
antecedents of mild cognitive impairment.  
Is mild cognitive impairment in general, and the impairment that precedes Alzheimer’s 
disease in particular, one step in a process that has additional clinical antecedents?  
Support for this view can be extrapolated from findings of neuropathological studies, 
which show that Alzheimer’s disease-related neuropathological findings, including 
neurofibrillary changes, seem to occur decades before the overt appearance of dementia. (107)  
It has been recognised for many years that many healthy older people have subjective 
complaints of cognitive decline. As noted earlier in this Seminar, the GDS staging procedure 
differentiates individuals with such symptoms, but who are otherwise free of clinical signs 
from healthy older people who are free of complaints of impairment.  
In 1986, a US National Institute of Mental Health workgroup proposed an entity—age-
associated memory impairment— to characterise healthy individuals at least 50 years of age 
with subjective complaints of memory loss and performance on a recent memory test at least 1 
SD below the mean established for young adults. (108)  
A similar entity with somewhat modified specific psychometric and other criteria has 
been proposed by Levy.(109) The prognostic relevance of subjective cognitive complaints in 
older people, without reference to psychometric test data, has been investigated in several 
studies, most of which have noted relations between subjective complaints and future 
cognitive decline.( 110, 113)  
 21 
For example, Reisberg and associates (114) are finding a fivefold greater likelihood of 
decline to mild cognitive impairment or dementia, over a 7-year mean follow-up interval, in 
people with subjective complaints compared with similarly aged individuals who are free of 
subjective complaints of impairment.  
Wolf and co-workers (115) reported a significant difference in urinary cortisol 
concentrations between older individuals with and without subjective complaints, perhaps, in 
part, a marker of concerns of older people about these self-perceived deficits, since cortisol 
concentrations are a well-known marker of stress.  
As an entity that precedes mild cognitive impairment, studies are presently noting that 
about 7–8% of otherwise healthy older people with subjective cognitive impairment progress 
to mild cognitive impairment or overt dementia every year. (114, 116)  
Hence, findings of several longitudinal studies lend support to the belief that mild 
cognitive impairment, with subtle but manifest clinical signs, is a stage in a clinical process 
that might be subjectively evident many years earlier.  
Although, current estimates need to be examined in much greater detail in future 
studies, it has been suggested that the subjective cognitive impairment stage before mild 
cognitive impairment could last for about 15 years.(117)  
Hence, the appearance of mild cognitive impairment seems to be on a clinical 
continuum that is preceded by subjective cognitive impairment. 
 
 
 
 
 
 
 
 
3. AIMS 
 
 22 
Although MCI encompasses a broad variety of subjects at elevated risk for subsequent 
progression to dementia, this population remains relatively heterogeneous and includes many 
subjects whose cognitive and functional abilities may remain stable or even improve. 
Therefore, the main purpose of neurologist, psychiatrist and genecitist is to identify as soon as 
possible which are the variables linked to a high risk of developing dementia as well as to start 
treatments of delaying dementia. 
Among the various proposed tools for identifying the MCI individuals with high-risk to 
develop dementia, such as neuroimaging, CSF biomarkers, the role of neuropsychological 
assessment and behavioural evaluation have been suggested. 
 
Accordingly the general aims of this study were:  
1. First (main aim). To evaluate the frequency and the relationship between behavioral 
and psychological symptoms in different MCI subtypes after stratification for age, 
education and sex 
 
Particularly specific aims of this research are: 
 
 Second. To evaluate if the severity of BPSD correlates with the degree of cognitive 
deficts in different tasks of cognition 
 
 
 Third To evaluate the association between behavioral and psychological symptoms in 
different neuroimaing pattern. 
 
 
 
 
 
4. MATERIALS AND METHOD 
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4.1 THE COGNITIVE IMPAIRMENT THROUGH AGEING (CogItA) STUDY  
 
The study sample included subjects will be selected from the Cognitive Impairment Through 
Aging Study (CogItA) a longitudinal, memory clinic study regarding aging, cognitive 
impairment and dementia carried out in subjects aged 50 or over who were recruited over a 
10-year period at the Memory Clinic, Dept. of Neurology and Rehabilitation, AOUP. “P. 
Giaccone”, University of Palermo (Chief: Prof. Rosolino Camarda) from 2000 to 2011. 
All included subjects have been evaluated with a multidimensional protocol including 
demographic characteristics, medical history, pharmacological treatments, clinical, 
neuropsychological and neurological examination, standard laboratory blood tests and 
neuroimaging study. When available, subjects were evaluated annually. The study at baseline 
comprised over 3548 subjects; approximately for one-third of these 3-year follow-up data are 
available. Written informed consent has be obtained from healthy subjects enrolled in the 
study as well as from caregivers of subjects with MCI at study enrolment.  
For this research we recruited only the healthy patients and patents with a clinical diagnosis of 
MCI according to the common criteria established by Winblad et. al. (2004) in the first K 
Symposium about mild cognitive impairment and the controls. (118)  
 
4.2 MULTIDIMENSIONAL PROTOCOL FOR MCI  
 
Neuropsychological tests were administered in an approximately one hour and half session. 
Cognitive and functional test scores are recorded in the database for each participant at 
baseline and annually. This protocol was administered by  trained physicians and 
neuropsychologists in a quite environment.    
Specifically the multidimensional protocol includes the following: 
 
a. The Global Cognitive Assessment was composed by the Mini Mental State 
Examination (119) and the Montreal Cognitive Assessment (120). 
b. Functional Scales included the Activity of Daily Living  and the Instrumental Activity 
of Daily Living.  
c. Behavioural Scales included: the Neuropsychiatric Inventory (121). 
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d. Finally Neuropsychological Testing includes tests evaluating memory, attention and 
concentration, visuo-spatial ability, language, praxic and executive functioning. 
 
a. Global Cognitive Assessment 
 
Mini Mental State Examination  
 
 The MMSE is a widely clinical instrument used for the preliminary screening of cognitive 
status in adults. The MMSE has demonstrated validity and reliability in psychiatric, 
neurologic, geriatric, and other medical populations.  It is a brief test (takes only 5-10 minutes) 
composed by 11-question that tests five areas of cognitive function: orientation in time, 
orientation in place, registration, attention and calculation, recall, and language. 
The maximum score on the Mini Mental State Exam is 30. The normal value is also corrected 
for degree of schooling and age. 
In general, scores fall into four categories:  
24-30: normal range 
20-23: mild cognitive impairment or possible early stage/mild disease 
10-19: middle stage/moderate dementia 
0-9: late stage/severe dementia 
The MMSE has lacked sensitivity to mild degrees of impairment (119). With the conventional 
cut-off level at 24 for dementia, the test has only a 6-point scale for discrimination between 
MCI or very mild dementia and normal functioning, with score overlap and skew as a result of 
the test’s ceiling. The MMSE has become a benchmark against which newer tests are 
compared to establish their improved sensitivity to mild degrees of impairment. (122) 
 
Montreal Cognitive Assessment  
 
The MoCA is a 30-point test administered in 10 minutes and evaluate multiple cognitive 
domains.  
Details on the specific MoCA items are as follows: 
- The short-term memory recall task (5 points) involves two learning trials of five nouns 
and delayed recall after approximately 5 minutes.  
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- Visuo-spatial abilities are assessed using a clock-drawing task (3 points) and a three-
dimensional cube copy (1 point).  
- Multiple aspects of executive functions are assessed using an alternation task adapted 
from the Trail Making B task (1 point), a phonemic fluency task (1 point), and a two-
item verbal abstraction task (2 points).  
- Attention, concentration, and working memory are evaluated using a sustained 
attention task (target detection using tapping; 1 point), a serial subtraction task (3 
points), and digits forward and backward (1 point each).  
- Language is assessed using a three-item confrontation naming task with low-
familiarity animals (lion, camel, rhinoceros; 3 points), repetition of two syntactically 
complex sentences (2 points), and the aforementioned fluency task. 
-  Finally, orientation to time and place is evaluated (6 points). 
 
The MoCA has been found to have good internal consistency and test-retest reliability and was 
able to correctly identify 90% of a large sample of a-MCI subjects from two different clinics 
(120). 
 
b. Functional Scale  
 
Activity of Daily Living  
 
Reflects basic and important general tasks (such as bathing, dressing, eating, transferring in or 
out of a bed or chair and using the toilet). The score ranges from 0 (total dependence) to 6 
(complete independence). 
 
Instrumental Activity of Daily Living  
 
It includes activities essential for making an independent life in the community (such as 
managing money, doing heavy or light housework, taking  medication, shopping, preparing 
meals and use telephone). The score ranges from 0 (total dependence) to 8 (complete 
independence). 
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c. Behavioural Scale 
 
Neuropsychiatric Inventory  
 
The Neuropsychiatric Inventory (NPI) (tab.5) was developed to assess psychopathology in 
dementia patients. It is a structured interview of caregiver and assess 12 behaviours on the 
basis of frequency and severity in the past month such as delusions, hallucinations, agitation, 
dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, wandering, night-time behavior 
disturbances, and appetite and eating abnormalities. 
Each sub-scale has an entry question inquiring whether the disturbance had been present in the 
last month. If the answer is affirmative, the caregiver is asked to rate specific neuro-
behavioural symptoms within each sub-scale on a four-point frequency and on a three-point 
severity scale. Frequency and severity scores are multiplied for each sub-scale (composite 
score) and added together for the total NPI score. The composite score of each sub-scale 
ranges between 0 and 12, and the total composite score between 0 and 144 according to the 
severity and frequency of NPS. For the purpose of the study, NPS were recorded both as 
continuous than as present (NPI score ≥1) or absent (NPI score = 0). The scale has a high level 
of internal consistency reliability, inter-rater reliability and the test–retest reliability, and has 
been validated in Italian subjects (121, 123). 
 
d. Neuropsychological Tests 
 
Neuropsychological testing (tab.4) has been conducted using some cognitive test included in 
the Mental Deterioration Battery (MDB) (124) as well other tasks such as Token (126) and 
Visual Search (126) previously validated in Italian subjects. 
For each test of the battery, Italian normative data for score adjustment based on sex, age and 
education were available and for each test a normative cut-off score corresponding to the 
lower limit of the tolerance interval on a 95% one-tailed test, for a confidence level of 95%, 
was calculated on the scores obtained by the healthy subjects of the standardisation sample 
(125; 126). 
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Briefly cognitive tests used were: 
Memory: the Rey Auditory-Verbal Learning Test (RAVLT) immediate and delayed 
and the Story Prose (127), which measure the learning capacity  and long term memory and 
the prose memory respectively.  
The RAVLT takes approximately 10 to 15 minutes to administer and consists of five 
presentations of a 15-word list, followed by a free recall trial after a 15 minute delay. Score on 
this test range from (0-75 points). 
The Story Recall requires the immediate and delayed recall of a short story, exploring 
the memory of 27 complex verbal stimuli (127). Subjects are asked to recall as many items of 
the story as possible soon after initial presentation, then the examiner repeats the whole story 
at the subject but the delayed recall is evaluated fifteen minutes later without further 
repetition. Score on this test range from (0-27 points). 
While the first test evaluate long term memory as well as short term memory, the second 
evaluate only the long term memory and the capacity to retain new information about events 
or facts, enabling retrieval when needed at a future time.  
Executive functions: we used the Raven Coloured Matrices, the Phonemic Fluency Test 
(127) and the Frontal Assessment Battery (128);  
The Raven's Progressive Matrices are a series of multiple-choice items that evaluate 
abstract non-verbal reasonin. It consists of three sets (A, B, Ab) from the standard matrices 
and each set includes 12 items. Score range from 0 to 36. Most of the items are presented on a 
coloured background to make the test more conspicuous for the participants. But the last few 
items in set B are kept black on white background.  
Phonemic Fluency Test assess the timed production of words after phonemic cues (A, F 
and S). The number of words reported in 1 minute for each letter was recorded. A cumulative 
score for the three letters was calculated (127).  
The Frontal Assessment Battery (128) consists of six subtests exploring the following: 
conceptualization, mental flexibility, motor programming, sensitivity to interference, 
inhibitory control, and environmental autonomy. It takes approximately 10 minutes to 
administer. Score range from 0 to 18. 
Attentive functions: we used the Trail Making Test and the Visual Search (126);  
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The Trail Making Test consisted of two parts. Part A, which required the subject to 
sequentially connect with a pencil 25 circled numbers irregularly distributed on a paper sheet, 
principally assessed psychomotor speed. Part B, which required the subject to connect circled 
letters and numbers alternating between the two sequences, assessed the mental flexibility 
needed for continuously shifting between the alphabetical and numerical series. The time 
required to complete each part of the task was recorded. The extra-time required to complete 
part B with respect to part A reflects shifting ability subtracted from psychomotor speed 
involved in both tasks. 
The Visual Search Test measures the recognition of visual stimuli (digits) arranged 
randomly on a matrix made up of 13 rows and 10 digits for each row. There are three different 
subtests, each with a number of stimuli to be recognized. This test evaluates selective visual 
attention and control of impulsiveness towards recognizing the wrong stimulus. The score is 
given by the number of correct answers (range 0-60) and omissions (range 0-60). 
Language: the Token Test (126) and the Aachener Aphasie Test. 
The Token Test (126) detects speech receptive disturbances in aphasics. It requires 20 
tokens, varying in shape (circle and square), size (small and large), and colour (red, yellow, 
green, blue and white). The test has 36 commands, each of which requires the manipulation or 
the attention to one or more tokens. The items are simple and complex and the score for each 
item is 0 if  the answer is wrong, 0.5 if an item is missed initially but is correct after the 
repetition, 1 if the answer is correct. 
The Aachener Aphasie Test is a battery composed by six tests. It measures aphasia (a 
disturbance of comprehension and formulation of language). It results from disturbance of the 
translation from words into thoughts and vice versa. Aphasia is produced by damage of 
cortical regions which are related to language functions.  
In our neuropsychological battery we used only the fifth test, the confrontation naming test 
(score range: 0 to 120) that evaluates the capability of the patient to describe things or 
situations or  actions with the right words. It consists of four subtests (score range: 0 to 30 
points): nouns, colour terms, compound nouns, sentences.  
Visuo-spatial abilities: the Visual Object and Space Perception;  
The VOSP consist of nine tests each designed to assess a particular aspect of object or 
space perception. In our neuropsychological battery we used the subtest 7 (position 
discrimination) that consists of two adjacent horizontal squares, one with a black dot (5 mm) 
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printed exactly in the centre and one with a black dot just off centre. It is composed by twenty 
stimuli and the score range from 0-20 in relation with a correct choises. 
Praxic function were investigated by using the Costructive Praxic (126). It assess the 
capacity of the subject to copy simple and complex geometric figures. The score ranges from 0 
to 14. 
 
Memory Assessment Clinics-Questionnaire: for detecting the degree of subjective 
awareness of the memory deficit we have used the Memory Assessment Clinics-Questionnaire 
(MAC-Q) (129). Subjects were asked to rate their present ability with six daily memory 
activities (e.g., remembering telephone numbers or where they put objects) in respect to the 
past. For each item the score ranged from 1 (ability better than in the past) to 5 (ability greatly 
worsened with respect to the past) with the overall score ranging from 5 to 30. A score ≥ 25 
gives a measures of significant subjective cognitive complain.  
 
e. Neuroimaging Assessment 
 
The subject was assessed with CT or MRI by different neuroimaging pattern specifically:  
Normal: Normal imaging 
Vascular: Leukoaraiosis and/or lacunae  
Degenerative: Atrophy (cortical and/or subcortical) 
Mixed: Vascular plus degenerative lesions 
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Rey words immediate and delayed recall (Rey, 1958) 
MEMORY 
Story Recall (Novelli et al, 1986) 
Raven Coloured Matrices (Raven, 1938) 
Letter Fluency (Novelli et al, 1986) EXECUTIVE 
Frontal Assessment Battery (Dubois et al, 2000) 
Trail Making Test (Reitan, 1958) 
ATTENTION 
Visual Search (Spinnler e Tognoni, 1987) 
Token Test (Spinnler e Tognoni, 1987) 
LANGUAGE 
Aachener Aphasie Test (De Bleser et al, 1986) 
VISUO-SPATIAL ABILITY Visual Object and Space Perception (K. Warrington, 1991) 
PRAXIC Constructive Apraxia (Spinnler e Tognoni, 1987) 
(Tab. 4 Neuropsychological Battery) 
  NA Never Frequency Severity S x F 
Delusion X 0 1 2 3 4 1 2 3 ___________ 
Hallucination X 0 1 2 3 4 1 2 3 ___________ 
Agitation X 0 1 2 3 4 1 2 3 ___________ 
Depression X 0 1 2 3 4 1 2 3 ___________ 
Anxiety X 0 1 2 3 4 1 2 3 ___________ 
Euphory X 0 1 2 3 4 1 2 3 ___________ 
Apathy X 0 1 2 3 4 1 2 3 ___________ 
Disinibition X 0 1 2 3 4 1 2 3 ___________ 
Irritability X 0 1 2 3 4 1 2 3 ___________ 
Wandering  X 0 1 2 3 4 1 2 3 ___________ 
Sleep X 0 1 2 3 4 1 2 3 ___________ 
Appetite  X 0 1 2 3 4 1 2 3 ___________ 
Total |__|__|__| 
 (Tab. 5 Neuro Psychiatric Inventory) 
Frequency 
0= Never 
1= Rarely 
2= Sometimes 
 
3= Frequently 
4= Almost always 
             Severity  1= light (not caused disorder in patients) 
                   2= moderate (caused disorder in patients) 
                                  3= severe (Drugs, more  serius for patients)  
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4.3 INCLUSION and EXCLUSION CRITERIA FOR MCI DIAGNOSIS 
 
As previously stated, MCI was diagnosed according to revised criteria proposed by Winblad et 
al. (2004) (118). General criteria include: 
 
 MMSE: score ≥ 23,75 (119) 
 
 CDR: score range 0.5 (questionable dementia) 
 
 Normal functioning in the activities of daily living with none of slight impairment in 
the instrumental activities of daily living  
 
 At least deficit in one of the neuropsychological tests that evaluate cognitive domains. 
Subjects were considered to have impaired performance in the cognitive domains if 
their performance on at least one test was at least 1.5 standard deviations below 
published age and education matched normative means 
 
 
The MCI diagnosis was classified as follows:  
 
1) a-MCI, subjects with memory deficits, defined as a pathological score in at least 1 
standardized memory test, with no deficits in other cognitive tests;  
2) snm-MCI, subjects with deficit in one single non-memory domain, defined as an 
abnormal test performance (under normality cut-off) in 1 non-memory test;  
3)  md-MCI-a, subjects with 1 abnormal test in at least 2 domains, one of which was 
memory impairment;  
4) md-MCI-na, subjects with 1 abnormal test in at least 2 domains, excluding memory. 
 
Inclusion criteria for healthy control subjects will be a MMSE score ≥27. Exclusion criteria 
for all included groups will be the presence of clinically severe psychiatric or systemic 
disease, mental retardation, severe sensory impairment (blindness, deafness), other 
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neurological conditions associated with cognitive impairment, a history of alcohol or 
substance abuse or dependence, head injury with loss of consciousness.  
 
4.4 STATISTICAL ANALYSES 
 
T-tests (and χ2-tests when appropriate) and one-way ANOVA were used to compare 
demographic and neuropsychological variables between groups. All analyses were performed 
through the software SPSS (SPSS Inc., Chicago, III, USA). 
 
 
4.5 GENERAL CHARACTERISTIC OF INCLUDED SUBJECTS  
 
 
The study sample includes patients that completed all the neuropsychological battery in day-
hospital regime  and was composed by five groups of subjects, as follows: 
The group was composed by 3548 subjects: 2162 (60,9%) female and 1386 (39,1%) male 
(Tab.6). This research was composed by two parts we named Study I and Study II. 
Sample
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39,1
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100,0
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Sex
%
Female
Male
 
(Tab. 6 Sex Distribution of Sample) 
In the Study I the sample was composed by 5 diagnostical group (Tab.7): amnestic MCI single 
domain (aMCI), amnestic MCI multiple domain (aMCImd), single non memory MCI 
(snMCI), non amnestic MCI multiple domain (naMCImd) and control group. 
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The first group with diagnosis amnestic MCI (aMCI) was composed by 433 (12,2%) subjects 
(56% female). The second group with diagnosis of amnestic MCI multiple domain (aMCImd) 
was composed by 621 (17,5%) subjects (51,4% female). The third group with diagnosis of non 
amnestic MCI single domain (snMCI) was composed by 324 (9,1% female) subjects (62,3% 
female). The fourth group with diagnosis of non amnestic MCI multiple domain (aMCImd) 
was composed by 174 (4,9%) subjects (62,3% female) The fifth group Control Group was 
composed by 1996 (56,1%) subjects (64,7% female) (Tab 8). The statistical distribution of sex 
showed that the memory complain was more frequently in male than in female, and in male 
the memory domain was more frequently associated with other pathological domain.  
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Tab.7 Diagnosis Distribution 
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Tab.8 Sex Distribution in MCI and Normal Sample 
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The education of participants ranged between 0 (illiterate) to 17 (graduate). As we will see by 
the statistical analysis of the demographic characteristic our sample showed lower education 
level in MCI than in Control Group. More specifically the mean of age in aMCI is 7,9 (±4,7) 
years of education, in the aMCImd group is 6.3(±4,2) years of education, in the snMCI is 6,3 
(±4,3) years of education, in the naMCImd is 5,4 (±3,6) years of education, and in the Control 
Group is 8,4 (±4,5) years of education (Tab 9).  
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Tab.9 Education distribution in MCI and Normal Sample-mean and standard deviation 
 
Age of participants ranged between 50 and 90 years. The age’s means in aMCI subjects was 
62,7±10,7, in aMCImd subjects was 69,7±9,0, in snMCI subjects was 70,7±9,9, in naMCImd  
subjects was 73,4±8,8 and in Control Group is 62,7±10,7. Totally the MCI Group is more 
elderly than Control Sample, and the naMCImd was more elderly than other MCI subtypes 
(Tab. 10).  
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Tab.10 Age distribution in MCI and Normal Sample-mean and standard deviation 
 
The cognitive characteristics of the sample, as expected, showed that the MMSE score was 
significantly higher in controls than in all MCI groups, and in those who showed an 
impairment of only one cognitive domain compared to those who showed a multiple domain 
impairment. More specific the means of MMSE in aMCI is 26,6 ± 1,9, in aMCImd is 25,5± 
1,6, in snMCI is 26,8±2,0, in naMCImd is 25,7±1,7 and in Control Group is 28,4±1,5 
(Tab.11). 
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Tab.11 MMSE Score in MCI and Normal Sample-mean and standard deviation 
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The same characteristic was have been shown in Moca test. More specifically the means of 
Moca in aMCI was 18,4±4,7, in aMCImd was 13,6±4,5, in snMCI was 17,4±4,5, in naMCImd 
was 13,6±4,5 and in Control Group was 21,7±4,6 (Tab.12). 
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Tab.12 Moca Score in MCI and Normal Sample-mean and standard deviation 
 
The daily base ability was more significantly preserved in Control Group than in MCI 
subjects, and in aMCI than MCI with more domain compromise, whereas daily instrumental 
ability was more preserved in control group than MCI, and it was more compromise in MCI 
multiple domain than in MCI with deficit in a single domain. More specifically the means of 
compromise items ADL in aMCI was 0,3±0,5, in aMCImd was 0,5±0,7, in snMCI was 
0,3±0,6, in naMCImd was 0,4±0,7 and in Control Group was 0,2±0,4, and the means of 
compromise items IADL in aMCI was 0,6±1,1, in aMCImd was 1,0±1,3, in snMCI was 
0,5±1,0, in naMCImd was 0,9±1,1 and in Control Group was 0,2±0,5 (Tab.13; Tab. 14). 
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Tab.13 ADL Score in MCI and Normal Sample-mean and standard deviation 
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Tab.14 IADL Score in MCI and Normal Sample-mean and standard deviation 
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Table 15 (Demographical and cognitive feature in MCI and Control Same -mean and standard deviation-Anova-
one way for continuous data and χ 2 for dicotomic data) 
 
The study II was composed by two parts, in the first part we selected only MCI sample. The 
MCI was classificated in aMCI+, composed by aMCI and aMCImd, and naMCI+ composed 
by snMCI and naMCImd.(Tab.16)  
Tot N. 1552 N. naMCI+ N. aMCI+   
  N. 498 N. 1054 P 
 Mean±SD Mean±SD  
Age 71,7±9,6 69,7±9,4 0,000 
Education 6±4,1 6,9±4,5 0,000 
MMSE-Z 26,4±2,0 26±1,8 0,000 
MOCA 16,2±4,9 15,5±5,2 0,107 
ADL 0,4±0,6 0,4±0,7 0,827 
IADL 0,7±1,1 0,9±1,3 0,005 
Sex F% 62,5 53,7  0,001 
Table 16 (Demografical and cognitive feature in aMCI+ and naMCI+ -mean and standard deviation-Anova-one 
way for continuous data and χ 2 for dicotomic data) 
 
The first group with diagnosis of amnestic MCI Plus (aMCI+) was composed by 1054 subjects 
(53,6% female). The second group with diagnosis of non amnestic MCI plus (naMCI+) was 
composed by 498 subjects (62,5% female). The statistical distribution of sex showed that the 
memory complain was more frequently in male than in female and the aMCI+ was younger 
Normal aMCI snMCI aMCImd naMCImd P 
1996 433 324 621 174 
Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD 
Age 62,7±10,7 69,7±9,9 70,7±9,9 69,7±9,0 73,4±8,8 0,000 
Education 8,4±4,5 7,9±4,7 6,3±4,3 6,3±4,2 5,4±3,6 0,000 
Sex F % 64,7 56,0 62,3 51,4 62,3 0,000 
MMSE 28,4±1,5 26,6±1,9 26,8±2,0 25,5±1,6 25,7±1,7 0,000 
ADL_Diff 0,2±0,4 0,3±0,5 0,3±0,6 0,5±0,7 0,4±0,7 0,000 
IADL_Diff 0,2±0,5 0,6±1,1 0,5±1,0 1±1,3 0,9±1,1 0,000 
MOCA 21,7±4,6 18,4±4,7 17,4±4,5 13,6±4,5 13,6±4,5 0,000 
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than naMCI+. The age’s means in aMCI+ is 69,7±9,4, in naMCI+ is 71,7±9,6 (Tab. 4). The 
instrumental ability was more preserved in naMCI+ than in aMCI+, indeed IADL means in 
aMCI+ was 0,9±1,3 and in naMCI+ was 0,7±1,1. the MMSE score was more elevated d in 
naMCI+ than in aMCI+. 
In the second part of Study II we selected MCI subjects with neuroimaging report (N.895) and 
for each MCI group we selected MCI with normal, degenerative and vascular neuroimaging 
report obtaining: aMCI+ with normal (N.243), degenerative (N.145) and vascular (N.223) 
neuroimaging report and naMCI+ with normal (N.122), degenerative (N.45) and vascular 
(N.117) neuroimaging report. 
The sample with Normal neuroimaging report naMCI+ differed from aMCI+ only by MMSE 
score, in fact in aMCI+ the MMSE mean was 26,3±1,8 while in naMCI+ means was 26,7±2,0; 
so aMCI+ obtained worse score in MMSE than naMCI+ (Tab.17). 
Normal naMCI aMCI P 
N.366 N.122 N.244   
Age 64,8±9,4 63,6±8,9 0,241 
Edu 6,2±4,2 6,9±4,4 0,128 
MMSE-Z 26,7±2,0 26,3±1,8 0,031* 
MOCA 18,4±4,7 17±4,9 0,084 
ADL_Diff 0,3±0,5 0,3±0,5 0,671 
IADL_Diff 0,4±0,9 0,5±0,9 0,229 
sex F 66,4(81) 62,7(153)  0,488 
Table 17 (Demografical and cognitive feature in aMCI+ and naMCI+ in Normal imaging Pattern-mean and standard deviation-Anova-one 
way for continuous data and χ 2 for dicotomic data) 
 
In the sample with Degenerative neuroimaging report naMCI+ differed from aMCI+ only by 
age, in fact in aMCI+ the age’s mean was 72,4±7,9 while in naMCI+ age’s means was 
76,4±8,1; so naMCI+ was more elderly than naMCI+(Tab.18). 
Degenerative 
      
N.200 naMCI aMCI P 
  N.47 N.153   
Age 76,4±8,1 72,4±7,9 0,003* 
Edu 6,5±3,9 6,7±4,6 0,822 
MMSE-Z 26±1,8 25,6±1,7 0,231 
MOCA 14,7±5,9 12,5±4,4 0,097 
ADL_Diff 0,3±0,6 0,3±0,7 0,957 
IADL_Diff 0,6±1 0,9±1,4 0,130 
sex F 63,8(30) 57,5(88)   
Table 18 (Demografical and cognitive feature in aMCI+ and naMCI+ in Degenerative imaging Pattern-mean and standard deviation-Anova-
one way for continuous data and χ 2 for dicotomic data) 
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In the sample with Vascular neuroimaging report naMCI+ differed from aMCI+  by MMSE 
score, in fact in aMCI+ the MMSE mean was 25,8±1,7 while in naMCI+ means was 26,8±2,0; 
so aMCI+ obtained worse score in MMSE than naMCI+. The aMCI+ group was younger than 
the MCI+ in fact age’s mean of naMCI+ was 68,3±9,3 and age’s mean of aMCI+ was 
66,2±9,4. Moreover the male subjects was more frequently associated with amnestic decline, 
in particular 48,9 % of aMCI+ and 62,9 % of naMCI+ was female.(Tab19) 
Vascolar naMCI aMCI P 
N.339 N.116 N.223   
Age 68,3±9,3 66,2±9,4 0,046* 
Edu 6,1±4 6,9±4,6 0,122 
MMSE-Z 26,8±2 25,8±1,7 0,000* 
MOCA 15,8±4,6 16,2±5,3 0,593 
ADL_Diff 0,4±0,6 0,4±0,7 0,745 
IADL_Diff 0,7±1,1 0,9±1,3 0,401 
sex F 62,9(73) 48,9(109) 0,014* 
Table 19 (Demografical and cognitive feature in aMCI+ and naMCI+ in Vascular imaging Pattern-mean and standard deviation-Anova-one 
way for continuous data and χ 2 for dicotomic data) 
 
4.5 NEUROCOGNITIVE CHARACTERISTIC OF INCLUDED SUBJECTS  
The Neurocognitive Characteristics of the sample were investigated by a comprensive Battery 
of Neuropsychologic test. The Battery was included test to examinated Memory, Executive, 
linguistic, attentive and praxic function. 
In Study I as we expected  the Normal subject to obtain better score in all screening and 
amnestic MCI obtain worse score in memory tests. Executive functions, attention, praxic and 
linguistic functions seemed more preserved in aMCI than in the other MCI subtype, and in 
snMCI than in aMCImd and naMCImd, although naMCImd showed worse attention 
performance. The visuopercective performance was preserved in MCI with normal memory 
performance (Tab.20). 
In the first part of Study II the aMCI+ group showed better performance in executive, attentive 
and praxic functions than naMCI+. As we expected the memory performance was more 
impaired in aMCI+ than in naMCI+, of course this impairment was evident in all different 
Neuroimaging pattern. Whereas in Normal and Degenerative pattern the aMCI+ persisted the 
worse performance of attention in naMCI+ than in aMCI+(Tab. 21, 22, 23, 24).  
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Total Control aMCI snMCI aMCImd naMCImd P 
 N. 3547 N.1995 N.433 N.324 N.621 N.174  
  Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD  
REYImm 39,4±6,1 27,9±5,7 35,7±5,6 26,1±4,7 34,3±4,5 0,000 
REYDiff 8,5±4,1 4,5±2,1 7,7±1,9 4,2±1,8 6,9±1,5 0,000 
BrRac 13,2±2,9 7,9±3,0 12,4±3,0 7,9±3,7 11,8±2,5 0,000 
FlSeT 14,4±7,5 14,6±6,0 16,1±7,5 12,5±5,5 15,8±8,0 0,000 
Memory 
MACQ 25,2±4,3 27,3±4,5 25,2±5,2 27,3±5,4 25,4±6,1 0,000 
FAB 16,3±1,9 15,6±2,1 14,1±2,4 12,4±2,7 12,2±2,6 0,000 
Rav 26,5±4,4 25,5±4,5 23,3±4,9 21,1±4,9 19,9±4,7 0,000 
Executive 
FlFoT 33,6±7,5 26,2±6,7 23,2±6,5 20,3±6,9 19,3±6,5 0,000 
Aech 114,4±5,2 110,7±7,2 107,4±9,2 102±13,7 102,1±13,2 0,000 Language 
TokTest 31,7±1,8 30,7±2,0 29,4±3,0 27,2±4,1 27,3±4,3 0,000 
MAt_P 45,3±7,3 41±6,4 37,5±8,2 33,5±8,5 33,3±8,2 0,000 
TrMTA 60,4±25,8 69,1±29,2 125,5±78,9 147,3±84,0 187,5±87,1 0,000 
TrMTB 112,6±71,3 150,7±91,3 240±154,7 265,5±132,3 329±144,2 0,000 
Attention 
TrMTBA 55±60,2 85,1±79,9 145,2±123,6 150,1±109,3 182,2±117,9 0,000 
VOSP 19,3±1,4 18,9±1,5 18,3±2,1 17,3±3,1 17,1±2,9 0,000 Visuospatial 
Prassic AprCo 11,9±1,6 11,8±1,3 11±1,8 10,8±2,3 10,4±2,3 0,000 
Table 20 (Neuro-cognitive feature in MCI and Normal sample-mean and standard deviation-Anova-one way for 
continuous data and χ 2 for dicotomic data) 
 
 
 
 
  
naMCI aMCI   
 N.1584 N.504 N.1080 P 
REYImmC 35,3±5,3 26,7±5,2 0,000* 
REYDiffC 7,4±1,8 4,3±1,9 0,000* 
Racconto 12,2±2,9 7,9±3,4 0,000* 
F-semant 16±7,6 13,3±5,8 0,000* 
Memory 
MACQ 25,3±5,5 27,3±5,1 0,000* 
FAB 13,3±2,7 13,4±2,9 0,517 
Raven 22,1±5,1 22,9±5,2 0,006* 
Executive 
F-fonem 21,9±6,8 22,7±7,4 0,044* 
Aechener 105,5±11,0 105,6±12,2 0,850 Language 
Token 28,7±3,6 28,7±3,8 0,962 
Matrici 36,1±8,4 36,6±8,5 0,256 
Trail-A 146±86,8 117,9±78,4 0,000* 
Trail-B 266,3±156,3 203,7±125,5 0,000* 
Attention 
Trail B-A 156,3±122,3 115,2±99,8 0,000* 
VOSP 17,8±2,5 17,8±2,9 0,686 Visuospazial 
Praxic Apr Cost 10,8±2,0 11,2±2,0 0,002* 
Table 21 (Neuro-cognitive feature in aMCI+ and naMCI+ -mean and standard deviation-Anova-one way for 
continuous data and χ 2 for dicotomic data) 
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Normal 
Neuroimaging  naMCI+ aMCI+  
N. 366 
 
N.122 N.244 P 
 
 
Mean±SD Mean±SD  
REYImmC 35,4±5,8 27±5,6 0,000* 
REYDiffC 7,4±2 4,7±2,1 0,000* 
Racconto 11,9±2,9 8±3,1 0,000* 
F-semant 15,6±7,9 13,3±6,2 0,005* 
Memory 
MACQ 26,7±5,5 27±5,2 0,661 
FAB 14,3±2,8 14±2,8 0,535 
Raven 22,9±5,4 23±5,2 0,858 
Executive 
F-fonem 22,9±7,2 23,6±7,3 0,386 
Aechener 108,7±9 107,9±11,9 0,539 Language 
Token 29,6±3,3 29±3,8 0,173 
Matrici 36,1±7,5 37,6±8,5 0,083 
Trail-A 115,4±67,6 97,7±64,8 0,081 
Trail-B 246,4±158,8 175,9±121,7 0,006* 
Attention 
Trail B-A 146,6±120,4 100,6±96,1 0,020* 
VOSP 18,1±2,4 17,9±3,1 0,657 Visuospazial 
Praxic Apr Costrut 10,9±2,3 11,3±1,9 0,083 
Table 22 (Neuro-cognitive feature in aMCI+ and naMCI+ in Normal imaging Pattern-mean and standard 
deviation-Anova-one way for continuous data and χ 2 for dicotomic data) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 23 (Neuro-cognitive feature in aMCI+ and naMCI+ in Degenerative imaging Pattern-mean and standard 
deviation-Anova-one way for continuous data and χ 2 for dicotomic data) 
Degenerative 
Neuroimaging  naMCI+ aMCI+   
N.200 
 
N.47 N.153 P 
 
 
Mean±SD Mean±SD 
 
REYImmC 35,8±5,2 26,8±5,2 0,000* 
REYDiffC 7,5±1,8 4±1,7 0,000* 
Racconto 11,4±2,2 7,5±3,3 0,000* 
F-semant 18,1±9,3 14,2±6,8 0,004* 
Memory 
MACQ 22,8±9 27,9±4,4 0,000* 
FAB 12,7±2,9 13,1±2,7 0,579 
Raven 21,8±6 22,1±5,1 0,757 
Executive 
F-fonem 21,9±7,3 22,6±7,3 0,564 
Aechener 104,7±8 104,8±12,2 0,946 Language 
Token 28,9±2,8 28,3±3,8 0,363 
Matrici 35,6±9,4 36,1±7,7 0,735 
Trail-A 162,4±81,2 124,4±67,1 0,023* 
Trail-B 332,9±183,7 255±145,9 0,120 
Attention 
Trail B-A 203,1±154,9 155,7±131 0,273 
Apr Costrut 11,4±1,9 11,2±2,1 0,551 Visuospatial 
Praxic VOSP 18,3±2,5 18±2,4 0,679 
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Vascular 
Neuroimaging  naMCI aMCI P 
N.339  N.116 N.223  
  Mean±SD Mean±SD 
 
REYImmC 36,2±5,3 26,5±5,2 0,000* 
REYDiffC 7,7±2 4,3±2 0,000* 
Racconto 12,4±2,7 8,3±3,5 0,000* 
F-semant 15,8±2,7 12,8±5,6 0,000* 
Memory 
MACQ 25,9±2 28,3±4,7 0,000* 
FAB 13,2±4,2 13,3±3 0,944 
Raven 22,5±7,6 22,8±5,2 0,591 Executive 
F-fonem 22±4,9 22,1±8 0,914 
Aechener 105,3±7,1 106±11,7 0,624 Language Token 28,5±12,8 28,4±3,7 0,892 
Matrici 37,6±3,8 36±8,5 0,091 
Trail-A 142,4±90,4 118,3±85,5 0,082 
Trail-B 200,5±127,6 196,7±131,3 0,888 Attention 
Trail B-A 107,8±93,7 108,2±104,2 0,986 
Apr Costrut 10,7±8,4 11,1±2 0,106 Visuospatial 
Praxic VOSP 17,6±2,7 17,5±2,8 0,899 
Table 24 (Neuro-cognitive feature in aMCI+ and naMCI+ in VascularNormal imaging Pattern-mean and standard 
deviation-Anova-one way for continuous data and χ 2 for dicotomic data) 
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5. RESULTS AND DISCUSSIONS 
 
5.1 RESULTS AND DISCUSSION OF STUDY 1 
The aim of the Study I was to evaluate the presence of BPSD in four subtypes of MCI and a 
Control Group. We correlated the scores obtained in specific NPI (frequenty x severity)  (the 
results are showed in the table IV). Among NPI items, we have evaluated the correlation 
between 12 items (Delusions, Hallucinations, Agitation/Aggression, Depression, Anxiety, 
Euphoria, Apathy, Disinhibition, Irritability, Wandering, Sleep, Eating Disorder) and the 
different types of diagnosis (aMCI, aMCImd, snMCI, naMCImd and Control Group) and the 
total score and the different types of diagnosis (Tab. 25). 
  
Normal 
(A) 
aMCI 
(B) 
aMCImd 
(C) 
snMCI 
(D) 
naMCImd 
(E) P 
 
Mood related features 
 
NPI_Depression 2,9 3,3 3,9 3,3 3,3 0,001 A<C 
NPI_Anxiety 3,1 3,2 3,7 3,3 3,6 N.S.  
NPI_Apathy 0,8 1,7 2,8 1,7 2 0,001 A<B,C,D,E C>B,D 
Psichothyc related 
features 
 
NPI_Delusion 0,05 0,2 0,3 0,1 0,3 N.S.  
NPI_Alllucination 0,05 0,1 0,3 0,1 0,3 N.S.  
Frontal related features 
 
NPI_Euphory 0,03 0,1 0,1 0,1 0,05 N.S.  
NPI_Agitation 0,2 0,6 0,7 0,6 0,8 0,001 A<C,E 
NPI_Disinibition 0,1 0,3 0,3 0,2 0,2 N.S.  
NPI_Irritability 1 1,6 2,3 1,8 2,2 0,001 A<B,C,D,E B<C 
Other related features 
 
NPI_Wandering 0,05 0,35 0,44 0,06 0,4 N.S. A<C 
NPI_Sleep 2,71 2,72 2,86 2,94 2,87 0,001  
NPI_Appetite 0,41 0,74 1,28 0,91 0,99 0,001 A<C 
NPI_Total 11,4 14,9 18,8 14,7 16,9 0,001  
Table 25 (Behavioural feature in MCI+ and in Normal Sample- χ 2 for dicotomic data) 
 
Totally the Normal subjects presented a lower NPI total score than MCI subject, and MCI with 
only one cognitive domain deficit presented total score lower than MCI multiple domain 
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deficit. We divided the NPI item in four categories: Mood related features included 
Depression, anxiety and apathy; psychotic related features included delusion and 
hallucination; frontal related features included agitation, irritability, euphoria, disinhibition, 
and other related features include wandering, sleep and appetite. 
In Mood relates features depression was most significantly present in aMCImd than in Normal 
subjects, and apathy was most significantly present in MCI than in Normal subjects and in 
aMCImd than  in MCI with only one cognitive domain deficit. According to Frontal related 
features agitation score was more elevated in MCI with more cognitive deficits than in Normal 
group and irritability score was more elevated in MCI than in Normal group and in aMCImd 
than in aMCI. Finally in Other related group wandering and appetite was more presented in 
aMCImd than in Normal group. 
 
5.2 RESULTS AND DISCUSSION OF STUDY II 
The study II was composed by two part: in the first part we selected the MCI subject (N.1552) 
in two group: MCI with amnestic deficit  (N. 1054) (aMCI+) and MCI without amnestic 
deficit (N.498) (naMCI+). The aim of the first part of second study was to evaluate the 
presence of BPSD in this two subtypes of MCI (aMCI+ and naMCI+). 
According to first step of the Study II the subjects aMCI+ shows more elevated level of 
depression, euphoria, apathy, and appetite than naMCI+. (Tab. 26) 
N. 1552 naMCI+ aMCI+ P 
NPI % N. 498 N. 1054  
Delusion 1,7 3,1 0,106 
Hallucinations  1,9 3,0 0,204 
Agitation 10,0 9,0 0,535 
Depression 51,0 58,0 0,011* 
Anxiety 50,8 54,8 0,151 
Euphoria 0,4 1,7 0,035* 
Apathy 26,3 35,1 0,001* 
Disinhibition 2,7 3,7 0,330 
Irritability 26,5 28,9 0,330 
Wondering 1,9 6,4 0,000* 
Sleep 42,5 41,7 0,760 
Appetite  11,7 16,9 0,009* 
NPI Tot 79,8 83,5 0,075 
Table 26 (Behavioural feature in aMCI+ and naMCI+ χ 2 for dicotomic data) 
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In the second part we selected MCI with neuroimaging report (N.895) and for each MCI group 
we selected MCI with normal, degenerative and vascular neuroimaging report, so we obtained: 
aMCI+ with normal (N. 243), degenerative (N.145) and vascular (N.223) neuroimaging report 
and naMCI+ with normal (N. 122), degenerative (N.45) and vascular (N.117) neuroimaging 
report. The aim of this second part was evaluated the presence of BPSD in this two subtypes 
MCI according to the different neuroimaging pattern (tab. 26, 27, 28). 
 
 
Table 26 (Behavioural feature in Normal Image             Table 27 (Behavioural feature in Degenerative Image 
aMCI+and naMCI+ χ 2 for dicotomic data)                                           aMCI+ and naMCI+ χ 2 for dicotomic data) 
 
 
 
 
 
 
 
 
 
 
Normal 
Neuroimaging naMCI+ aMCI+ P 
N. 366 N.122 N.244 
 
NPI % 
      
Delusion 0,0 2,1 0,118 
Hallucinations  0,9 1,7 0,548 
Agitation 8,6 7,5 0,705 
Depression 51,7 57,7 0,289 
Anxiety 50,9 57,7 0,225 
Exaltation No No   
Apathy 23,3 22,1 0,801 
Disinibition 2,6 2,1 0,760 
Irritability 20,7 24,2 0,465 
Wondering 1,7 3,3 0,389 
Sleep 46,6 42,5 0,470 
Appetite and 
weight 8,6 12,9 0,234 
NPI Tot 78,4 79,3 0,861 
Degenerative  
Neuroimaging naMCI+ aMCI+ P 
N.200 N.47 N.153  
NPI % 
      
Delusion 2,3 2,1 0,923 
Hallucinations  0,0 1,4 0,437 
Agitation 7,0 6,9 0,994 
Depression 37,2 57,6 0,019 
Anxiety 44,2 48,6 0,610 
Exaltation 0,0 2,8 0,269 
Apathy 14,0 38,9 0,002 
Disinibition 0,0 1,4 0,437 
Irritability 16,3 31,3 0,055 
Wondering 2,3 6,9 0,259 
Sleep 39,5 38,9 0,936 
Appetite and 
weight 9,3 17,4 0,200 
NPI Tot 74,4 88,9 0,018 
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Vascular  
Neuroimaging naMCI+ aMCI+ P 
N.339 N.116 N.223  
NPI %       
Delusion 0,9 1,8 0,499 
Hallucinations  0,9 2,7 0,261 
Agitation 12,2 10,4 0,624 
Depression 53,0 62,0 0,114 
Anxiety 56,5 59,7 0,571 
Exaltation 1,7 1,8 0,963 
Apathy 26,1 38,5 0,023 
Disinibition 1,7 5,0 0,144 
Irritability 31,3 33,0 0,748 
Wondering 0,9 5,0 0,054 
Sleep 45,2 46,2 0,870 
Appetite and 
weight 13,9 21,3 0,101 
NPI Tot 81,7 88,2 0,103 
Table 28 (Behavioural feature in Degenerative Image aMCI+and naMCI+ χ 2 for dicotomic data) 
 
According to Normal Neuroimaging pattern there wasn’t difference in BPDS between aMCI+ 
and naMCI+. Instead the Degenerative pattern and in Vascular Pattern apathy was more 
frequently present in aMCI+ than in naMCI+, in fact in Vascular pattern the 38,5% of aMCI+ 
was apathetic while in naMCI the apathetic was 26,1%, and in Degenerative pattern the 
apathy’s frequency in aMCI+ was 38,9 % while in naMCI+ it was 14%. In the latter pattern 
the aMCI+ appeared more depressed than naMCI+ in particular the depression’s frequency in 
aMCI+ was 57,6% and in naMCI+ was 37,2%. 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
6. Conclusion 
A review of behavioural symptoms in different dementia subtypes found an increase in the 
risk of depression, emotional labiality, anxiety and apathy in vascular dementia compared to 
AD, while delusions, delusional misidentification, wandering and restlessness were less 
frequent in vascular dementia compared with Alzheimer’s disease (130). In our study of the 
population with MCI presented elevated frequency of BPSD than Normal group, in 
depression, apathy, irritability, agitation, wondering and appetite, and aMCImd present more 
elevated frequency of non cognitive characteristic. In amnestic compromise MCI the presence 
of vascular and degenerative disease significantly increased the frequency of apathy. While 
the presence of degenerative disease was associated with depression in aMCI+, suggesting that 
apathy as a preclinic symptom of dementia. Recent reviews have demonstrated a large 
variation in estimates of the prevalence of behavioural and psychological symptoms in MCI 
(6,7). This variation can in part be explained by different diagnostic criteria for MCI and use 
of different study settings. Most symptoms are less prevalent in the population than in clinical 
samples (6). Behavioural and psychological problems are common in dementia (4) and have 
become accepted as central characteristics of the disorder. Behavioural and psychological 
symptoms in dementia are at least as problematic for patients and caregivers as cognitive 
impairments, significantly affecting quality of life and cost of care of people with dementia 
(1,2). Furthermore, they currently offer greater opportunities for intervention and management 
than does cognitive impairment (3). Current definitions of MCI focus entirely on cognition 
and may exclude those with psychiatric symptoms on the basis that psychiatric disorders 
might underlie cognitive impairment which should then not be considered an indicator of 
incipient Alzheimer’s disease. Yet we have shown that many behavioural and psychological 
symptoms are present in those with mild cognitive impairments with a similar pattern of 
occurrence to that seen in individuals with dementia. Behavioural and psychological 
symptoms should be assessed as possible targets for management in cognitively impaired 
older people. Several studies in patients with MCI have shown that those with behavioural and 
psychological symptoms have an increased risk of dementia incidence and suggest that 
noncognitive symptoms should be a consideration when identifying those in the earliest stages 
of dementia (6,7). It remains difficult to differentiate patients with psychological symptoms as 
a consequence of early dementia from those in whom cognitive impairment is secondary to 
other psychological conditions. Further population-based longitudinal studies are needed to 
 49 
establish whether behavioural and psychological symptoms can be used alongside memory 
and other cognitive impairment to improve the identification of those at highest risk of 
dementia incidence. 
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